Bullish
Eli Lilly's stock rises 4.7% to $1,283.09 after strong Q2 earnings report.
Eli Lilly's stock surged 4.7% to $1,283.09 following a robust Q2 earnings report, with revenue up 48% to $23 billion, driven by Mounjaro and Zepbound sales. The company also raised its full-year revenue guidance to $85–87 billion.
Key points
- Eli Lilly's Q2 revenue increased by 48% to $23 billion, led by Mounjaro and Zepbound sales.
- The company raised its full-year revenue guidance to $85–87 billion, up from the previous $82–85 billion.
- Eli Lilly's stock price closed at $1,283.09, up 4.7% from the previous day.
Sources
AI-generated from public news sources. Not financial advice.
